Cargando…
1895. Omadacycline for the Treatment of Non-Pulmonary Mycobacterial Infections: a Single-Center Retrospective Review
BACKGROUND: Infections due to rapidly growing mycobacteria (RGM) such as M. abscessus, M. chelonae and M. fortuitum typically require long and toxic regimens, with complex resistance patterns and limited oral options further producing suboptimal efficacy. Since its approval in 2018, however, the tet...
Autores principales: | Shen, Edmund, Albin, John, Hysell, Kristen, Hurtado, Rocio M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679259/ http://dx.doi.org/10.1093/ofid/ofad500.1723 |
Ejemplares similares
-
Utilizing the Promise of Omadacycline in a Resistant, Non-tubercular Mycobacterial Pulmonary Infection
por: Minhas, Ramandeep, et al.
Publicado: (2019) -
1082. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2021) -
1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
por: Ghali, Amer El, et al.
Publicado: (2022) -
1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2020) -
1016. Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2022)